William Blair Has Optimistic Outlook of AWH FY2024 Earnings

Aspira Women’s Health Inc. (NASDAQ:AWH) – Research analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for Aspira Women’s Health in a report issued on Tuesday, November 26th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($1.07) per share for the year, up from their prior forecast of ($1.19). The consensus estimate for Aspira Women’s Health’s current full-year earnings is ($1.26) per share. William Blair also issued estimates for Aspira Women’s Health’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.57) EPS.

AWH has been the subject of a number of other reports. Alliance Global Partners decreased their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th. StockNews.com began coverage on shares of Aspira Women’s Health in a research note on Monday. They set a “hold” rating for the company.

Aspira Women’s Health Trading Up 6.6 %

Shares of NASDAQ AWH opened at $0.81 on Thursday. Aspira Women’s Health has a 12-month low of $0.67 and a 12-month high of $5.65. The company has a market cap of $13.50 million, a PE ratio of -0.67 and a beta of 1.44. The stock has a 50 day simple moving average of $0.83 and a 200-day simple moving average of $1.28.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities and Exchange Commission. 12.19% of the stock is currently owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.